Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer

Lack of sustained response to therapeutic agents in patients with KRAS-mutant lung cancer poses a major challenge and arises partly due to intratumor heterogeneity that defines phenotypically distinct tumor subpopulations. To attain better therapeutic outcomes, it is important to understand the diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Padhye, Aparna, Konen, Jessica M., Rodriguez, B. Leticia, Fradette, Jared J., Ochieng, Joshua K., Diao, Lixia, Wang, Jing, Lu, Wei, Solis, Luisa S., Batra, Harsh, Raso, Maria G., Peoples, Michael D., Minelli, Rosalba, Carugo, Alessandro, Bristow, Christopher A., Gibbons, Don L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492319/
https://www.ncbi.nlm.nih.gov/pubmed/34309585
http://dx.doi.org/10.1172/jci.insight.148392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492319/
https://www.ncbi.nlm.nih.gov/pubmed/34309585
http://dx.doi.org/10.1172/jci.insight.148392

Ejemplares similares